Adaptive Biotechnologies (ADPT)

Executive Summary

Adaptive Biotechnologies is a leader in immune medicine, leveraging its proprietary Immune Medicine Platform to decode T-cell and B-cell receptor genetics for diagnostics and therapeutics. Its commercial clonoSEQ assay is the only FDA-cleared test for minimal residual disease (MRD) in multiple myeloma and B-cell acute lymphoblastic leukemia, providing a recurring revenue stream. The company's therapeutic pipeline, though early-stage, targets hematologic malignancies including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma, with several Phase 2 trials ongoing. Adaptive's platform also enables discovery of novel TCR-based therapies and antibodies, positioning it to capitalize on the growing precision oncology market. Despite near-term headwinds from R&D spending and competition, the company's unique data assets and expanding clinical applications support a long-term growth outlook.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim data readout for venetoclax combination in CLL60% success
• Q4 2026Initiation of Phase 1 trial for multiple myeloma candidate (immunomodulatory + proteasome inhibitor)70% success